There is no cure for cold sores because the virus that causes them, herpes simplex virus type 1 (HSV-1), hides inside nerve cells in a dormant state that current medicines cannot reach. An estimated 3.8 billion people under age 50 carry this virus, about 64% of the global population. The biology of how HSV-1 conceals itself is remarkably sophisticated, and it explains why decades of antiviral research have fallen short.
How the Virus Hides in Your Nerves
Cold sores start as an active infection in the skin or mucous membranes around your mouth. But HSV-1 doesn’t stay there. It travels along nerve fibers into clusters of nerve cells called ganglia, typically the trigeminal ganglion near your jawline, which supplies sensation to your face. Once the virus reaches these neurons, it essentially goes to sleep.
The key to this disappearing act is the route the virus takes. When HSV-1 enters a nerve cell through the long, thin axon (the fiber that extends out toward the skin), the journey back to the cell’s core is so long that a critical viral protein loses its ability to activate the genes needed for replication. Without that activation signal, the virus never fully “turns on” inside the neuron. Instead, it slips into a silent, dormant state called latency. The viral DNA sits inside the nerve cell’s nucleus, intact but producing almost nothing, just a single set of molecules called latency-associated transcripts that help maintain the quiet.
The Virus Wraps Itself in Silence
Dormancy isn’t just a passive process. HSV-1 actively disguises its own DNA to avoid detection. Inside the nerve cell nucleus, the viral genes responsible for replication get tightly wound around proteins called histones, packed into a compressed form that the cell treats like its own inactive DNA. The virus’s latency-associated transcripts actually promote this packaging, adding chemical tags to the histones that signal “keep this shut down.” It’s the biological equivalent of locking your blueprints in a vault and throwing away the key.
Importantly, this silencing does not rely on permanently altering the viral DNA itself. The chemical tags on the histones are reversible, which is exactly what allows the virus to wake up later. The virus has evolved a system that is quiet enough to avoid immune detection but not so permanent that it can never reactivate.
Why Antivirals Can’t Finish the Job
The most common cold sore medications, like acyclovir and its relatives, work by mimicking a building block of DNA. When the virus is actively replicating, a viral enzyme converts the drug into its active form, which then jams the virus’s copying machinery. The viral DNA polymerase grabs the fake building block, incorporates it, and stalls. Replication stops.
This mechanism is remarkably selective. Uninfected cells barely activate the drug at all, which is why these medications have very low toxicity. But there’s a fundamental limitation: the drug only works when the virus is actively copying its DNA. During latency, HSV-1 is not replicating. It’s not producing the enzyme that activates the drug. The viral DNA is just sitting there, coiled up and silent inside a nerve cell. There is nothing for the medication to target. It’s like trying to stop a car that’s already parked.
This is why antivirals can shorten outbreaks and reduce their frequency but never eliminate the infection. They’re effective soldiers against an enemy that only occasionally shows itself.
What Triggers a Reactivation
The virus periodically wakes up and travels back down the nerve fiber to the skin, producing a new cold sore or sometimes shedding invisibly without symptoms. Known triggers include UV light exposure, physical or emotional stress, fever, illness, and hormonal changes. These aren’t random. They share a common thread: they activate stress-signaling pathways in neurons.
UV exposure, fever, and stress can all trigger the release of inflammatory molecules that increase nerve cell excitability. This hyperexcitability feeds into a specific stress pathway inside the neuron that ultimately loosens the chemical locks on the viral DNA, allowing replication genes to switch back on. Accumulated DNA damage in the nerve cell or a drop in the survival signals that neurons depend on can also tip the balance toward reactivation.
Even between visible outbreaks, the virus sheds from the skin more often than most people realize. At least 70% of people carrying HSV-1 shed the virus from the oral area at least once a month without any symptoms, and many shed it six or more times monthly. This invisible shedding is one reason HSV-1 spreads so efficiently.
The Immune System’s Incomplete Victory
Your immune system does fight HSV-1, and it fights hard. Specialized immune cells, particularly a type of white blood cell called CD8+ T cells, surround latently infected neurons in the ganglia. These T cells can detect traces of viral activity and suppress reactivation before it produces symptoms. In many cases, they succeed, which is why most reactivations are subclinical.
But the virus has a countermeasure. The latency-associated transcripts it produces during dormancy appear to increase the presentation of viral fragments to CD8+ T cells, paradoxically wearing them out over time. This process, called T-cell exhaustion, is similar to what happens in chronic infections like HIV or hepatitis. The immune cells become less effective, expressing fatigue markers on their surfaces. They don’t disappear entirely, but they lose their edge. The result is a stalemate: the immune system can limit the virus but never clear it, while the virus can reactivate but never overwhelm the host completely.
Gene Editing: The Closest Thing to a Cure
The most promising approach to actually curing HSV-1 involves physically cutting the viral DNA out of nerve cells. Researchers have developed specialized molecular scissors called meganucleases, delivered into neurons using harmless viral carriers (adeno-associated virus vectors). In mouse models of oral herpes infection, this approach has eliminated 90% or more of latent HSV-1 DNA from the ganglia, with some experiments reaching 97% elimination in genital infection models.
Recent work has focused on simplifying the treatment: using a single type of carrier virus, a single meganuclease that cuts the HSV genome in two places at once, lower doses, and neuron-specific targeting to reduce side effects. These refinements have improved tolerability while maintaining effectiveness. The results are striking in animals, but translating this to humans presents significant challenges. Human ganglia are larger and harder to reach, the doses needed are uncertain, and safety in human nerve tissue remains unproven.
Vaccine development is also active. Moderna has a therapeutic vaccine candidate, mRNA-1608, in early-stage clinical trials for people with recurrent herpes. Unlike a traditional vaccine designed to prevent infection, a therapeutic vaccine aims to boost the immune response in people already infected, potentially reducing outbreaks and shedding. This would not eliminate the virus but could change the experience of living with it substantially.
Cold Sores vs. Canker Sores
One point worth clarifying, since the two are often confused: cold sores and canker sores are entirely different conditions. Cold sores are clusters of small, fluid-filled blisters that form on the outside of the mouth, usually along the lip border. They’re caused by HSV-1 and are contagious. Canker sores are single, round, white or yellow ulcers with a red border that form inside the mouth, on the inner cheeks, lips, or tongue. They have no known cause and are not contagious. If your sores appear inside your mouth and don’t spread to others, they’re almost certainly canker sores, not herpes.